IGFBP3 CRISPR/Cas9 KO Plasmid (m): sc-421064
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- IGFBP3 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the IGFBP3 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: IGFBP3 Antibody (B-5): sc-365936
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IGFBP3 CRISPR/Cas9 KO Plasmid (m) | sc-421064 | 20 µg | $397.00 |
Overview
Igfbp3 encodes insulin-like growth factor binding protein 3 (IGFBP3), a secreted regulator that binds IGF-I and IGF-II to modulate their bioavailability, receptor engagement, and downstream signaling through the IGF axis. By shaping IGF-driven PI3K–AKT and MAPK/ERK pathway activity, IGFBP3 influences cell growth, survival, differentiation, and tissue remodeling in multiple mouse organs. IGFBP3 can also exert IGF-dependent and IGF-independent effects on apoptosis and stress responses through interactions with extracellular matrix components and cell-surface partners. Dysregulated Igfbp3 expression or IGF/IGFBP balance is frequently studied in contexts of abnormal growth control, metabolic regulation, inflammation, and oncogenic signaling networks.
IGFBP3 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Igfbp3 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Igfbp3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Igfbp3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish IGFBP3 protein expression.
This CRISPR knockout system enables efficient generation of Igfbp3-deficient cell models for investigation of IGFBP3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Igfbp3 exon(s) critical for IGFBP3 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Igfbp3 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by IGFBP3 CRISPR/Cas9 KO Plasmid (m) and IGFBP3 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Igfbp3 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by IGFBP3 HDR Plasmid (m) and IGFBP3 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Igfbp3 homology arms to support homology-directed repair at defined Igfbp3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.